{
  "document_id": "9d010f8e",
  "zip_file": "hffg0257.zip",
  "category": "Presentations",
  "content_file": {
    "file_name": "hffg0257.pdf",
    "file_path": "Presentations/hffg0257.zip/hffg0257.pdf",
    "extracted_text": "=== Page 1 ===\nDeveloping a path forward for market access \nNovember 2018 \nPrivileged: This presentation contains draft proposals for discussion by \nManagement and are subject to appropriate Purdue legal and regulatory review \nbefore they can be considered final. These materials are confidential and \nproprietary.\nSource:  https://www.industrydocuments.ucsf.edu/docs/hffg0257\n\n\n=== Page 2 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\n2\nNet sales1\n$M\n10\n11\n5\n43\n21\n31\n11\n5\n7\n5\n1\n1\n1\n10\n1\n1\n159\n53\n63\n113\n111\n73\n17\n18\n9\n15\n10\n6\n6\n17\n13\n6\n4\n545\n2019 contracting\nMarket \nsegment\nCommer-\ncial\nMedicare \nPart D\nCurrent status (FYE June 2018)\n1 Only account for discretionary rebates to payors, but not other GtN reductions; 2  Includes Admin fee and price protection when applicable; \n3 Assuming status carries over from 201807 period for \nthose accounts with OxyContin formulary access, status based on majority of lives; \n4 Excluding BCBS TN               5 Prime Therapeutics - excl HCSC: include BCBS NC, MN, KS Horizon BCBSNJ and other prime accounts \n21%\n17%\n13%\n21%\n23%\n20%\n4%\n9%\n3%\n5%\n26%\n14%\n14%\n15%\n17%\n14%\nGross sales\n$M \nMarket \nShare\n11%\n7%\n6%\n2%\n2%\n1%\n1%\n1%\n1%\n1%\n11%\n5%\n2%\n1%\n1%\n0%\n54%\n% \nNet sales \nAccount\nExpress Scripts4\nCaremark\nOptumRx  - United Healthcare\nAetna Health Plans\nPrime Therapeutics - excl HCSC5\nPrime Therapeutics - HCSC\nCigna Healthcare\nProcare\nBCBS FL (Prime Therapeutics)\nIndependence BCBS (PA)\nCaremark\nOptumRx  - United Healthcare\nExpress Scripts\nPrime Therapeutics\nEnvisionRx Options\nTotal\nMedImpact\n2T Preferred\nNOF\nNOF\n2T Preferred\nNOF\n3T Preferred\n3T Pref PDP/MAPD NOF\nPref MAPD/PDP NOF\n2T Preferred\n2T Preferred\n2T Preferred \n2T Preferred\n2T Preferred\n2T Preferred\nNOF\n2T Preferred\n42%\n35%\n38%\n21%\n28%\n29%\n0%\n20%\n0%\n0%\n56%\n66%\n38%\n40%\n37%\n28%\nRebate2\nOxyContin\nXtampza ER3\nNon-preferred\nPreferred\nPreferred\nNon-preferred\nPreferred\nNOF\nPreferred\nNOF\nNOF\nNOF\nNon-preferred\nNon-preferred\nPreferred\nNon-preferred\nPreferred\nPreferred\n2019 formulary status\nTBD\nTBD\nTBD\nTBD\nTBD\nTBD\nTBD\nTBD\nTBD\nTBD\n12/07/2018\n11/04/2018\n11/16/2018\n12/07/2018\n12/14/2018\n11/19/2018\n2020 Bid \ndue date\nSOURCE: Purdue internal data, MMIT\nLives \n992\n191\n5\n112\n26\n102\n21\n21\n12\n11\n7\n6\n258\n155\n26\n20\n8\nRe-\nevaluating \n2019 bid \ngiven the \nlatest event \nof Excellus \nBCBS \nexclusion \nOverview: top accounts for Oxycontin\nSource:  https://www.industrydocuments.ucsf.edu/docs/hffg0257\n\n\n=== Page 3 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nFact base for ESI modeling \n No. of lives: 817 K\nGross sales: $1.9 Mn\nNet sales: $1.9 Mn\n2018 formulary status: 3T Non-Preferred\n2019 contracting status: asked for 70% rebate to remain \ncurrent status, then excluded Oxycontin when we didn’t \naccept the rate; timeline of implementation TBD\nExcellus BCBS \nCommercial \nESI \ncommercial\n Fact base for modeling:\nNo. of lives: 42Mn\nGross sales: $191 Mn            \nNet sales: $111 Mn\nBlended rebate rate: 41.7%\n2018 formulary status: 2T Preferred - allows for class UM\n2019 contracting status: 42.5% rebate as the only preferred \nOxycodone ER, or 20% rebate as the non-preferred (but \nexclusive)\n Scenario for modeling\nESI overall:\nStatus quo:\n-\nMaintain current access \nstatus with the same rate \nExclusive: \n- 70% rebate for exclusive \npreferred status\nSource:  https://www.industrydocuments.ucsf.edu/docs/hffg0257\n\n\n=== Page 4 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nThe ERO market contraction of -21% at ESI Commercial is more severe than the overall market, \nyet OxyContin has grown its share of TRx in contrast to the broader market\na\n67.2\n69.6\n10.0\n7.5\n17.7\n16.6\n1.6\n2.4\n2017\n1.5\n2.0 1.9\n2018 \nHysingla ER\nOxyContin\nNucynta ER\nZohydro ER\nXtampza ER\nOther ERO brands2 \nERO Gx\nShare shift in ERO Commercial market1, % TRx\nOverall Commercial market\nESI Commercial\nSOURCE: IQVIA Plantrak\n1 Market share compared the first three quarters in 2017 and 2018 due to data limitation\n2 Other ERO brands include Avinza, Arymo ER, Embeda, Belbuca, Kadian, Opana ER, Butrans, Morphabond ER, Xartemis XR\nVolu\nme \nchan\nge \n-17.0%\n-20.9%\n61.9\n62.5\n11.9\n9.1\n20.4\n21.1\n2.5\n1.7\n1.1\n2017\n2.8\n2018 \nCurrent share of Oxycontin \nat  15.4%\n• The market \ncontraction of EROs at \nESI Commercial is 4pp \nmore severe than the \noverall market, but \nthere is a much lower \nshift towards \ngenerics\n• OxyContin has grown \nits market share in \nthe past year, along \nwith Xtampza ER and \nZohydro ER\nESI COMMERCIAL\nSource:  https://www.industrydocuments.ucsf.edu/docs/hffg0257\n\n\n=== Page 5 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nCurrent formulary coverage: ESI commercial\nOxyContin\nHysingla ER\nXtampza ER\nNucynta ER\nZohydro ER\nOxycontin preferred, Xtampza non-preferred\n25% Preferred\nPreferred\nNon-preferred\nPreferred\nNon-preferred\nOxycontin preferred, Xtampza not covered\n25% Preferred\nPreferred\nNot covered\nPreferred\nNot covered\nExclusive preferred\n19% Preferred\nNot covered\nNot covered\nNot covered\nNot covered\nNo brand covered\n9% Not covered\nNot covered\nNot covered\nNot covered\nNot covered\nOxycontin preferred, Xtampza non-preferred, others\n7% Preferred\nNot covered\nNon-preferred\nPreferred\nNot covered\nAll brands non-preferred\n6% Non-preferred\nNon-preferred\nNon-preferred\nNon-preferred\nNon-preferred\nOthers\n10%\nCoverage by product\nFormulary type\n% of lives\nSource:  https://www.industrydocuments.ucsf.edu/docs/hffg0257\n\n\n=== Page 6 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nESI commercial 2019 bid grid\nManufacturer:\nPurdue Pharma\nChannel:\nRetail/Mail/Specialty\nBase\nManaged Medicaid onlRestrictedunUnrestricted\nProduct\nRate Type\nFootnotes\nCPC*\nControlled  \n1 of Many\nControlled \n1 of 2\nControlled \nExclusive\nClosed \n1 of Many\nClosed \n1 of 2\nClosed \nExclusive\nNon-Preferred \nFormulary  Access \nRate - Restricted\nNon-Preferred \nFormulary\nAccess Rate - \nUnrestricted\nFootnotes\nEffective \nDate\nOxyContin\nUnrestricted Rebate\n1\nNarcotic Analgesics Oral\n24.000%\n42.500%\n42.500%\n24.000%\n42.500%\n42.500%\n1/1/2019\nOxyContin\nUnrestricted Rebate\n1, 6 Narcotic Analgesics Oral\n42.500%\nNo Bid\nNo Bid\n42.500%\nNo Bid\nNo Bid\n1/1/2019\nOxyContin\nRestricted\n1, 7, 9 Narcotic Analgesics Oral\n42.500%\n42.500%\n42.500%\n42.500%\n42.500%\n42.500%\nNo Bid\nNo Bid\n1/1/2019\nOxyContin\nRestricted\nNarcotic Analgesics Oral\nNo Bid\nNo Bid\nNo Bid\nNo Bid\nNo Bid\nNo Bid\nNo Bid\n20.000%\n1, 10\n1/1/2019\nOxyContin\nbase\n1, 8 Narcotic Analgesics Oral\n35.000%\n35.000%\n35.000%\n35.000%\n35.000%\n35.000%\n1/1/2019\nRebates - Stated as % of WAC\nRebates - Stated as % of WAC\nSource:  https://www.industrydocuments.ucsf.edu/docs/hffg0257\n\n\n=== Page 7 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nFOOTNOTES:\n6)  OxyContin (all strengths) must be listed as the only preferred extended release oxycodone Product on formulary.\nCarrier Name\nFormulary Name\nPriority Health\nPriority Health – COMMERCIAL\nPriority Health\nPriority Health – COMM/HCR\nWALT DISNEY COMPANY\nWALT DISNEY\n8) Utilization is eligible for this level of Rebate when OxyContin (all strengths) is subject to a limited prior authorization applied to all extended release opioids (brand and generic, existing and new product entrants) that is mutually \nagreed upon by both ESI and the Company to not be a restriction for purposes of this level of Rebate.  Any Utilization submitted under Formularies other than those listed here shall not be eligible for this Rebate.  Formulary Names \ncurrently eligible for this Rebate are:\n9)  Utilization is eligible for this level of Rebate when (i) OxyContin is Unrestricted on the lowest preferred brand tier, however, a prior authorization on all immediate release opioids (IROs) and extended release opioids (EROs) is \npermitted,  (ii) Plan has adopted the Express Scripts Advanced Opioid Management program (as described in footnote 7 herein), and (iii) OxyContin is listed as the only preferred extended-release oxycodone Product on formulary.  The \nAllowed Net WAC  for this rate shall be calculated by: multiplying the Net WAC as of June 30, 2018 by one (1) plus the Inflation Limitation Percentage.\n10)  Utilization is eligible for this level of Rebate when (i) OxyContin is Unrestricted on the non-preferred brand tier, however, a prior authorization on all immediate release opioids (IROs) and extended release opioids (EROs) is \npermitted,  (ii) Company is the Exclusive manufacturer on formulary with all competitor extended-release opioids not covered and requiring a step edit of either a generic ERO or OxyContin (current products subject to be this \nrequirement include: Avinza®, Kadian®, Duragesic®, Zohydro® ER, Embeda®, Exalgo®, Opana® ER, Belbuca®, Xtampza® ER and Nucynta® ER).  Rebates are only available on eligible claims from Plans with capability to do step \nedits and prior authorizations.\n1)  Quantity limits placed on Oxycontin of 2/day for all strengths will not be considered a restriction on Oxycontin.\nPain Severe Enough to Require Daily, Around-the-Clock, Long-Term Opioid Treatment.  Approve for 1 year if the patient meets ONE of the following criteria (A, B or C):\nA) The patient has a cancer diagnosis; OR\nB) The patient is in hospice program, end-of-life care, or palliative care; OR  \nC) The patient has chronic pain but does not have a cancer diagnosis.  Approve for 1 year if the patient meets ALL of the following criteria (i, ii, iii, iv, v, and vi):\ni. Patient is not opioid naïve; AND \nii. Patient has a concurrent prescription for a short-acting opioid; AND\niii. Non-opioid therapies (e.g., non-opioid medications [e.g., nonsteroidal anti-inflammatory drugs {NSAIDs}, tricyclic antidepressants, serotonin and norepinephrine reuptake inhibitors {SNRIs}, anticonvulsants], exercise therapy, \nweight loss, cognitive behavioral therapy) have been optimized and are being used in conjunction with opioid therapy according to the prescribing physician; AND \niv. The patient’s history of controlled substance prescriptions has been checked using the state prescription drug monitoring program (PDMP), unless unavailable in the state, according to the prescribing physician; AND\nv. Risks (e.g., addiction, overdose) and realistic benefits of opioid therapy have been discussed with the patient according to the prescribing physician; AND \nvi. Treatment plan (including goals for pain and function) is in place and reassessments (including pain levels and function) are scheduled at regular intervals according to the prescribing physician.\n7)  Utilization is eligible for this level of Rebate when OxyContin (all strengths) Unrestricted, however, the following Prior Authorization is permitted on Product provided it's applied equally to all other branded and generic long-\nacting opioids:\nSource:  https://www.industrydocuments.ucsf.edu/docs/hffg0257\n\n\n=== Page 8 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\n▪The ERO market contraction of -7% in \nCVS Caremark Medicare is nearly half \nthe rate of the broader Medicare ERO \ncontraction of -13% \n▪Within the overall Caremark ERO market, \nthe share of OxyContin rose by 0.4pp, \nbut within the major ERO brands1, \nOxyContin’s share fell 3pp (to 88%) while \nXtampza ER gained 2pp\n▪Caremark accounts for 53% of \nOxyContin’s contracted Medicare \ngross sales, with a above-average \nrebate rate of 56% total rebate for \n20192\n▪Purdue ERO portfolio has preferred \naccess in 79% of lives at CVS \nCaremark Medicare, while only 18% of \nlives receive non-preferred Xtampza \n▪If OxyContin is excluded while Xtampza ER \nis the preferred branded oxycodone ER, \nOxyContin will lose xx-xx% shares\n▪Given the downside of exclusion, \nOxyContin should increase rebate no more \nthan xx-xx%\n▪From CVS perspective, the tipping point \nfor excluding OxyContin will be xx-xx%\n▪For every 1pt of share loss, OxyContin will \nhypothetically be willing to increase \nrebate by xxpts to maintain current \naccess\n1\n2\nOther components that are \ncritical to the \nrecommendation, but do \nnot require debate\nKey components that \nrequire debate and \nalignment\nKey components of the OxyContin CVS Caremark Medicare bid\na\nb\n3\n4\nc\nd\nPRELIMINARY\nWIP\n1 OxyContin, Xtampza ER, Hysingla ER, Zohydro ER, Nucynta ER\n2 ~52% base rebate and 4.00% admin fee\nSource:  https://www.industrydocuments.ucsf.edu/docs/hffg0257\n\n\n=== Page 9 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nXtampza ER\nOxyContin\nNucynta ER\nHysingla ER\nZohydro ER\nOther ERO brands2 \nERO Gx\nShare shift in ERO Medicare market1, % TRx\nOverall Medicare market\nCaremarkPCS Medicare\nSOURCE: IQVIA Plantrak\n1 Market share compared the first three quarters in 2017 and 2018 due to data limitation\n2 Other ERO brands include Avinza, Arymo ER, Embeda, Belbuca, Kadian, Opana ER, Butrans, Morphabond ER, Xartemis XR\nVolu\nme \nchan\nge \n76.4\n76.7\n7.4\n5.5\n14.2\n14.1\n0.9\n0.5\n1.1\n1.6\n2017\n1.0\n2018 \n-13.1%\n-7.0%\nAt CVS/Caremark, OxyContin holds a larger share of the market and overall volume decline is \n6pp lower than the overall Medicare market\na\n65.1\n65.2\n7.9\n24.8\n25.2\n1.1\n0.7\n1.0\n2017\n0.2\n6.2\n2018 \nWe will focus on the \nmarket dynamics among \nleading ERO brands for \nOxyContin’s contracting \nstrategy analysis\n• OxyContin holds a \nlarger and growing \nshare of the ERO \nmarket at \nCVS/Caremark when \ncompared to the overall \nPart D market\n• Overall volume \nerosion at \nCVS/Caremark is \nnearly half that of the \noverall Part D market\nCAREMARKPCS\nSource:  https://www.industrydocuments.ucsf.edu/docs/hffg0257\n\n\n=== Page 10 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nCurrent coverage at CVS\nOxyContin Hysingla ERXtampza ERNucynta ERZohydro ER\nOxycontin and Hysingla preferred, Xtampza non-preferred\n53% Preferred\nPreferred\nNon-prefer Preferred\nNon-prefer\nNo brand covered\n18% Preferred\nPreferred\nNot covere Preferred\nNot covered\nNo Oxycodone ER covered\n15% Preferred\nNot covere Not covere Not coveredNot covered\nOxycontin preferred, Xtampza not covered\n4% Not coveredNot covere Not covere Not coveredNot covered\nOxycontin preferred, Xtampza non-preferred\n4% Preferred\nNot covere Non-prefer Preferred\nNot covered\nOthers\n6%\nFormulary type\n% of lives\nCoverage by product\nCurrent rebate rate: 56%\nAsk: maintain fixed net price – increasing \neffective rebate rate to 60% for the same \ncoverage\nSource:  https://www.industrydocuments.ucsf.edu/docs/hffg0257\n\n\n=== Page 11 ===\n \nDeveloping a path forward for market access \nNovember 2018 \nPrivileged: This presentation contains draft proposals for discussion by \nManagement and are subject to appropriate Purdue legal and regulatory review \nbefore they can be considered final. These materials are confidential and \nproprietary.\nSource:  https://www.industrydocuments.ucsf.edu/docs/hffg0257\n\n\n=== Page 12 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\n2\nNet sales1\n$M\n10\n11\n5\n43\n21\n31\n11\n5\n7\n5\n1\n1\n1\n10\n1\n1\n159\n53\n63\n113\n111\n73\n17\n18\n9\n15\n10\n6\n6\n17\n13\n6\n4\n545\n2019 contracting\nMarket \nsegment\nCommer-\ncial\nMedicare \nPart D\nCurrent status (FYE June 2018)\n1 Only account for discretionary rebates to payors, but not other GtN reductions; 2  Includes Admin fee and price protection when applicable; \n3 Assuming status carries over from 201807 period for \nthose accounts with OxyContin formulary access, status based on majority of lives; \n4 Excluding BCBS TN               5 Prime Therapeutics - excl HCSC: include BCBS NC, MN, KS Horizon BCBSNJ and other prime accounts \n21%\n17%\n13%\n21%\n23%\n20%\n4%\n9%\n3%\n5%\n26%\n14%\n14%\n15%\n17%\n14%\nGross sales\n$M \nMarket \nShare\n11%\n7%\n6%\n2%\n2%\n1%\n1%\n1%\n1%\n1%\n11%\n5%\n2%\n1%\n1%\n0%\n54%\n% \nNet sales \nAccount\nExpress Scripts4\nCaremark\nOptumRx  - United Healthcare\nAetna Health Plans\nPrime Therapeutics - excl HCSC5\nPrime Therapeutics - HCSC\nCigna Healthcare\nProcare\nBCBS FL (Prime Therapeutics)\nIndependence BCBS (PA)\nCaremark\nOptumRx  - United Healthcare\nExpress Scripts\nPrime Therapeutics\nEnvisionRx Options\nTotal\nMedImpact\n2T Preferred\nNOF\nNOF\n2T Preferred\nNOF\n3T Preferred\n3T Pref PDP/MAPD NOF\nPref MAPD/PDP NOF\n2T Preferred\n2T Preferred\n2T Preferred \n2T Preferred\n2T Preferred\n2T Preferred\nNOF\n2T Preferred\n42%\n35%\n38%\n21%\n28%\n29%\n0%\n20%\n0%\n0%\n56%\n66%\n38%\n40%\n37%\n28%\nRebate2\nOxyContin\nXtampza ER3\nNon-preferred\nPreferred\nPreferred\nNon-preferred\nPreferred\nNOF\nPreferred\nNOF\nNOF\nNOF\nNon-preferred\nNon-preferred\nPreferred\nNon-preferred\nPreferred\nPreferred\n2019 formulary status\nTBD\nTBD\nTBD\nTBD\nTBD\nTBD\nTBD\nTBD\nTBD\nTBD\n12/07/2018\n11/04/2018\n11/16/2018\n12/07/2018\n12/14/2018\n11/19/2018\n2020 Bid \ndue date\nSOURCE: Purdue internal data, MMIT\nLives \n992\n191\n5\n112\n26\n102\n21\n21\n12\n11\n7\n6\n258\n155\n26\n20\n8\nRe-\nevaluating \n2019 bid \ngiven the \nlatest event \nof Excellus \nBCBS \nexclusion \nOverview: top accounts for Oxycontin\n2\nSource:  https://www.industrydocuments.ucsf.edu/docs/hffg0257\n\n\n=== Page 13 ===\n \nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nFact base for ESI modeling \n No. of lives: 817 K\nGross sales: $1.9 Mn\nNet sales: $1.9 Mn\n2018 formulary status: 3T Non-Preferred\n2019 contracting status: asked for 70% rebate to remain \ncurrent status, then excluded Oxycontin when we didn’t \naccept the rate; timeline of implementation TBD\nExcellus BCBS \nCommercial \nESI \ncommercial\n Fact base for modeling:\nNo. of lives: 42Mn\nGross sales: $191 Mn            \nNet sales: $111 Mn\nBlended rebate rate: 41.7%\n2018 formulary status: 2T Preferred - allows for class UM\n2019 contracting status: 42.5% rebate as the only preferred \nOxycodone ER, or 20% rebate as the non-preferred (but \nexclusive)\n Scenario for modeling\nESI overall:\nStatus quo:\n-\nMaintain current access \nstatus with the same rate \nExclusive: \n- 70% rebate for exclusive \npreferred status\nSource:  https://www.industrydocuments.ucsf.edu/docs/hffg0257\n\n\n=== Page 14 ===\n \nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nThe ERO market contraction of -21% at ESI Commercial is more severe than the overall market, \nyet OxyContin has grown its share of TRx in contrast to the broader market\na\n67.2\n69.6\n10.0\n7.5\n17.7\n16.6\n1.6\n2.4\n2017\n1.5\n2.0\n1.9\n2018 \nHysingla ER\nOxyContin\nNucynta ER\nZohydro ER\nXtampza ER\nOther ERO brands2 \nERO Gx\nShare shift in ERO Commercial market1, % TRx\nOverall Commercial market\nESI Commercial\nSOURCE: IQVIA Plantrak\n1 Market share compared the first three quarters in 2017 and 2018 due to data limitation\n2 Other ERO brands include Avinza, Arymo ER, Embeda, Belbuca, Kadian, Opana ER, Butrans, Morphabond ER, Xartemis XR\nVolu\nme \nchan\nge \n-17.0%\n-20.9%\n61.9\n62.5\n11.9\n9.1\n20.4\n21.1\n2.5\n1.7\n1.1\n2017\n2.8\n2018 \nCurrent share of Oxycontin\nat  15.4%\n• The market \ncontraction of EROs at \nESI Commercial is 4pp \nmore severe than the \noverall market, but \nthere is a much lower \nshift towards \ngenerics\n• OxyContin has grown \nits market share in \nthe past year, along \nwith Xtampza ER and \nZohydro ER\nESI COMMERCIAL\nSource:  https://www.industrydocuments.ucsf.edu/docs/hffg0257\n\n\n=== Page 15 ===\n \n \n \nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nCurrent formulary coverage: ESI commercial\nOxyContin\nHysingla ER\nXtampza ER\nNucynta ER\nZohydro\nOxycontin preferred, Xtampza non-preferred\n25% Preferred\nPreferred\nNon-preferred\nPreferred\nNon-pre\nOxycontin preferred, Xtampza not covered\n25% Preferred\nPreferred\nNot covered\nPreferred\nNot cov\nExclusive preferred\n19% Preferred\nNot covered\nNot covered\nNot covered\nNot cov\nNo brand covered\n9% Not covered\nNot covered\nNot covered\nNot covered\nNot cov\nOxycontin preferred, Xtampza non-preferred, others\n7% Preferred\nNot covered\nNon-preferred\nPreferred\nNot cov\nAll brands non-preferred\n6% Non-preferred\nNon-preferred\nNon-preferred\nNon-preferred\nNon-pre\nOthers\n10%\nCoverage by product\nFormulary type\n% of lives\nSource:  https://www.industrydocuments.ucsf.edu/docs/hffg0257\n\n\n=== Page 16 ===\n \n \n \nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nESI commercial 2019 bid grid\nManufacturer:\nPurdue Pharma\nChannel:\nRetail/Mail/Specialty\nBase\nManaged Medicaid onlRestrictedunUnrestricted\nProduct\nRate Type\nFootnotes\nCPC*\nControlled  \n1 of Many\nControlled \n1 of 2\nControlled \nExclusive\nClosed \n1 of Many\nClosed \n1 of 2\nClosed \nExclusive\nNon-Preferred \nFormulary  Access \nRate - Restricted\nNon-Preferred \nFormulary\nAccess Rate - \nUnrestricted\nFootnotes\nEffective \nDate\nOxyContin\nUnrestricted Rebate\n1\nNarcotic Analgesics Oral\n24.000%\n42.500%\n42.500%\n24.000%\n42.500%\n42.500%\n1/1/2019\nOxyContin\nUnrestricted Rebate\n1, 6 Narcotic Analgesics Oral\n42.500%\nNo Bid\nNo Bid\n42.500%\nNo Bid\nNo Bid\n1/1/2019\nOxyContin\nRestricted\n1, 7, 9 Narcotic Analgesics Oral\n42.500%\n42.500%\n42.500%\n42.500%\n42.500%\n42.500%\nNo Bid\nNo Bid\n1/1/2019\nOxyContin\nRestricted\nNarcotic Analgesics Oral\nNo Bid\nNo Bid\nNo Bid\nNo Bid\nNo Bid\nNo Bid\nNo Bid\n20.000%\n1, 10\n1/1/2019\nOxyContin\nbase\n1, 8 Narcotic Analgesics Oral\n35.000%\n35.000%\n35.000%\n35.000%\n35.000%\n35.000%\n1/1/2019\nRebates - Stated as % of WAC\nRebates - Stated as % of WAC\nSource:  https://www.industrydocuments.ucsf.edu/docs/hffg0257\n\n\n=== Page 17 ===\n \n \n \nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nFOOTNOTES:\n6)  OxyContin (all strengths) must be listed as the only preferred extended release oxycodone Product on formulary.\nCarrier Name\nFormulary Name\nPriority Health\nPriority Health – COMMERCIAL\nPriority Health\nPriority Health – COMM/HCR\nWALT DISNEY COMPANY\nWALT DISNEY\n8) Utilization is eligible for this level of Rebate when OxyContin (all strengths) is subject to a limited prior authorization applied to all extended release opioids (brand and generic, existing and new product entrants) that is mutually \nagreed upon by both ESI and the Company to not be a restriction for purposes of this level of Rebate.  Any Utilization submitted under Formularies other than those listed here shall not be eligible for this Rebate.  Formulary Names \ncurrently eligible for this Rebate are:\n9)  Utilization is eligible for this level of Rebate when (i) OxyContin is Unrestricted on the lowest preferred brand tier, however, a prior authorization on all immediate release opioids (IROs) and extended release opioids (EROs) is \npermitted,  (ii) Plan has adopted the Express Scripts Advanced Opioid Management program (as described in footnote 7 herein), and (iii) OxyContin is listed as the only preferred extended-release oxycodone Product on formulary.  The \nAllowed Net WAC  for this rate shall be calculated by: multiplying the Net WAC as of June 30, 2018 by one (1) plus the Inflation Limitation Percentage.\n10)  Utilization is eligible for this level of Rebate when (i) OxyContin is Unrestricted on the non-preferred brand tier, however, a prior authorization on all immediate release opioids (IROs) and extended release opioids (EROs) is \npermitted,  (ii) Company is the Exclusive manufacturer on formulary with all competitor extended-release opioids not covered and requiring a step edit of either a generic ERO or OxyContin (current products subject to be this \nrequirement include: Avinza®, Kadian®, Duragesic®, Zohydro® ER, Embeda®, Exalgo®, Opana® ER, Belbuca®, Xtampza® ER and Nucynta® ER).  Rebates are only available on eligible claims from Plans with capability to do step \nedits and prior authorizations.\n1)  Quantity limits placed on Oxycontin of 2/day for all strengths will not be considered a restriction on Oxycontin.\nPain Severe Enough to Require Daily, Around-the-Clock, Long-Term Opioid Treatment.  Approve for 1 year if the patient meets ONE of the following criteria (A, B or C):\nA) The patient has a cancer diagnosis; OR\nB) The patient is in hospice program, end-of-life care, or palliative care; OR  \nC) The patient has chronic pain but does not have a cancer diagnosis.  Approve for 1 year if the patient meets ALL of the following criteria (i, ii, iii, iv, v, and vi):\ni. Patient is not opioid naïve; AND \nii. Patient has a concurrent prescription for a short-acting opioid; AND\niii. Non-opioid therapies (e.g., non-opioid medications [e.g., nonsteroidal anti-inflammatory drugs {NSAIDs}, tricyclic antidepressants, serotonin and norepinephrine reuptake inhibitors {SNRIs}, anticonvulsants], exercise therapy, \nweight loss, cognitive behavioral therapy) have been optimized and are being used in conjunction with opioid therapy according to the prescribing physician; AND \niv. The patient’s history of controlled substance prescriptions has been checked using the state prescription drug monitoring program (PDMP), unless unavailable in the state, according to the prescribing physician; AND\nv. Risks (e.g., addiction, overdose) and realistic benefits of opioid therapy have been discussed with the patient according to the prescribing physician; AND \nvi. Treatment plan (including goals for pain and function) is in place and reassessments (including pain levels and function) are scheduled at regular intervals according to the prescribing physician.\n7)  Utilization is eligible for this level of Rebate when OxyContin (all strengths) Unrestricted, however, the following Prior Authorization is permitted on Product provided it's applied equally to all other branded and generic long-\nacting opioids:\nSource:  https://www.industrydocuments.ucsf.edu/docs/hffg0257\n\n\n=== Page 18 ===\n \n \n \nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\n▪The ERO market contraction of -7% in \nCVS Caremark Medicare is nearly half \nthe rate of the broader Medicare ERO \ncontraction of -13% \n▪Within the overall Caremark ERO market, \nthe share of OxyContin rose by 0.4pp, \nbut within the major ERO brands1, \nOxyContin’s share fell 3pp (to 88%) while \nXtampza ER gained 2pp\n▪Caremark accounts for 53% of \nOxyContin’s contracted Medicare \ngross sales, with a above-average \nrebate rate of 56% total rebate for \n20192\n▪Purdue ERO portfolio has preferred \naccess in 79% of lives at CVS \nCaremark Medicare, while only 18% of \nlives receive non-preferred Xtampza \n▪If OxyContin is excluded while Xtampza ER \nis the preferred branded oxycodone ER, \nOxyContin will lose xx-xx% shares\n▪Given the downside of exclusion, \nOxyContin should increase rebate no more \nthan xx-xx%\n▪From CVS perspective, the tipping point \nfor excluding OxyContin will be xx-xx%\n▪For every 1pt of share loss, OxyContin will \nhypothetically be willing to increase \nrebate by xxpts to maintain current \naccess\n1\n2\nOther components that are \ncritical to the \nrecommendation, but do \nnot require debate\nKey components that \nrequire debate and \nalignment\nKey components of the OxyContin CVS Caremark Medicare bid\na\nb\n3\n4\nc\nd\nPRELIMINARY\nWIP\n1 OxyContin, Xtampza ER, Hysingla ER, Zohydro ER, Nucynta ER\n2 ~52% base rebate and 4.00% admin fee\nSource:  https://www.industrydocuments.ucsf.edu/docs/hffg0257\n\n\n=== Page 19 ===\n \n \n \nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nXtampza ER\nOxyContin\nNucynta ER\nHysingla ER\nZohydro ER\nOther ERO brands2 \nERO Gx\nShare shift in ERO Medicare market1, % TRx\nOverall Medicare market\nCaremarkPCS Medicare\nSOURCE: IQVIA Plantrak\n1 Market share compared the first three quarters in 2017 and 2018 due to data limitation\n2 Other ERO brands include Avinza, Arymo ER, Embeda, Belbuca, Kadian, Opana ER, Butrans, Morphabond ER, Xartemis XR\nVolu\nme \nchan\nge \n76.4\n76.7\n7.4\n5.5\n14.2\n14.1\n0.9\n0.5\n1.1\n1.6\n2017\n1.0\n2018 \n-13.1%\n-7.0%\nAt CVS/Caremark, OxyContin holds a larger share of the market and overall volume decline is \n6pp lower than the overall Medicare market\na\n65.1\n65.2\n7.9\n24.8\n25.2\n1.1\n0.7\n1.0\n2017\n0.2\n6.2\n2018 \nWe will focus on the \nmarket dynamics among \nleading ERO brands for \nOxyContin’s contracting \nstrategy analysis\n• OxyContin holds a \nlarger and growing \nshare of the ERO \nmarket at \nCVS/Caremark when \ncompared to the overall \nPart D market\n• Overall volume \nerosion at \nCVS/Caremark is \nnearly half that of the \noverall Part D market\nCAREMARKPCS\nSource:  https://www.industrydocuments.ucsf.edu/docs/hffg0257\n\n\n=== Page 20 ===\n \nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nCurrent coverage at CVS\nOxyContin Hysingla ERXtampza ERNucynta ERZohydro ER\nOxycontin and Hysingla preferred, Xtampza non-preferred\n53% Preferred\nPreferred\nNon-prefer Preferred\nNon-prefer\nNo brand covered\n18% Preferred\nPreferred\nNot coveredPreferred\nNot covered\nNo Oxycodone ER covered\n15% Preferred\nNot covere Not coveredNot coveredNot covered\nOxycontin preferred, Xtampza not covered\n4% Not covere Not covere Not coveredNot coveredNot covered\nOxycontin preferred, Xtampza non-preferred\n4% Preferred\nNot covere Non-prefer Preferred\nNot covered\nOthers\n6%\nFormulary type\n% of lives\nCoverage by product\nCurrent rebate rate: 56%\nAsk: maintain fixed net price – increasing \neffective rebate rate to 60% for the same \ncoverage\nSource:  https://www.industrydocuments.ucsf.edu/docs/hffg0257\n",
    "extraction_method": "pymupdf+ocr",
    "errors": [],
    "success": true
  },
  "metadata_file": {
    "file_name": "hffg0257-info.pdf",
    "file_path": "Presentations/hffg0257.zip/hffg0257-info.pdf",
    "extracted_text": "=== Page 1 ===\nnull - hffg0257 - Downloaded 31/03/2025 11:11:32 AM\nDocument Information\nTitle: 20181203 Purdue market access strategy PS_v1.pptx\nURL: https://www.industrydocuments.ucsf.edu/docs/hffg0257\nAuthor: Xiaodong Zhang\nDocument Date: 2019 October 27\nType: Presentation\nGenre: Microsoft PowerPoint 2016\nPages: 20\nID: hffg0257\nCollection: McKinsey Documents\nDrug: Buprenorphine; Hydrocodone; Hydrocodone Bitartrate; Morphine; Oxycodone; \nOxymorphone; Tapentadol\nAvailability: public; no restrictions\nBates Number: MCK-MAAG-4851037\nDate Added UCSF: 2022 June 06\nCite This Document\nAuthor. Title. Date. Year. Collection. Source. https://www.industrydocuments.ucsf.edu/docs/[ID]\nXiaodong Zhang. 20181203 Purdue market access strategy PS_v1.pptx. 2019 October 27. \nMcKinsey Documents. Unknown. https://www.industrydocuments.ucsf.edu/docs/hffg0257\nArtifacts\n1.\t hffg0257.zip [ 789.38 kb]\n",
    "extraction_method": "pymupdf+ocr",
    "errors": [],
    "success": true
  },
  "processed_at": "2025-06-12T13:49:41.659861",
  "overall_success": true
}